Drug intelligence / Profile preview

AJA002

Development stage: Unknown
Lead developer: AJNA
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

**AJA002** is an investigational, standardized full-spectrum psilocybin-based botanical tryptamine formulation from AJNA BioSciences for generalized anxiety disorder. AJNA describes it as a daily microdose-oriented novel antidepressant formulation intended to provide a more targeted and potentially safer botanical alternative to conventional antidepressants; its precise composition, dosage form, route, and receptor-subtype pharmacology have not been publicly disclosed. The company lists the program as entering Phase 1 development. ([ajnabiosciences.com](https://ajnabiosciences.com/pipeline/))

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on AJA002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AJA002.

Explore the full profile